Somatostatinoma Terminated Phase 2 Trials for Everolimus (DB01590)

Also known as: Somatostatinomas

IndicationStatusPhase
DBCOND0000820 (Somatostatinoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02031536Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With SurgeryTreatment
NCT02273752Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTreatment